JAK3: Tyrosine-protein kinase JAK3
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation.
- Drugs that act on it: 11
- With a US drug page: 2
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Ritlecitinib | Approved | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | Boxed warning |
| Upadacitinib | Approved | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | Boxed warning |
| AT-9283 | — | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | — |
| Cerdulatinib | — | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | — |
| Decernotinib | — | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | — |
| Filgotinib | — | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | — |
| R-333 | — | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | — |
| R-348 | — | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | — |
| Ruxolitinib | — | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | Boxed warning |
| Tricetamide | — | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | — |
| WHI-P131 | — | Tyrosine-protein kinase JAK3 inhibitor | Inhibitor | — |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- T-B+ severe combined immunodeficiency due to JAK3 deficiency
- 0.84
- Myelofibrosis
- 0.61
- Atopic eczema
- 0.59
- Alopecia areata
- 0.57
- Crohn disease
- 0.56
- Acquired polycythemia vera
- 0.55
- Graft versus host disease
- 0.54
- Vitiligo
- 0.52
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- JAK3
- Related
- Janus Kinase (JAK)
Drugs and mechanisms are from ChEMBL CHEMBL2148 (CC BY-SA 3.0). Gene name, function (UniProt P52333, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets